RSS   Newsletter   Contact   Advertise with us
Post Online Media

Alessandro Riva to join Gilead as senior vice president

Alessandro RivaGilead Sciences, Inc., a biopharmaceutical company, announced that Alessandro Riva will join the company as senior vice president, hematology and oncology therapeutic area head.

Dr. Riva will also join Gilead’s Executive Committee. Dr. Riva joins Gilead from Novartis Oncology, where he served as Head, Global Oncology Development.

Article continues below

READ MORE Gilead names Kevin Young COO

Dr. Riva was responsible for the development of more than 20 cancer compounds, including targeted and immune-oncology therapies and for many worldwide regulatory approvals of innovative medicines in both solid and hematological malignancies.

He was also a member of the Novartis Oncology Division Executive Committee, Development Committee, Translational and Early Development Committee and Innovation Management Board. During his 12 year tenure at Novartis he was involved in several worldwide drug approvals.

Prior to joining Novartis, Dr. Riva co-founded the Breast Cancer International Research Group (BIRG) and Cancer International Research Group (CIRG), for which he served as Chief Executive Officer and Chief Medical Officer.

He received his bachelor’s degree in Medicine and also a Certificate Board in Oncology/Hematology from the School of Medicine of Milan. He began his career at the University Hospital of Milan where he treated patients with hematological malignancies.

He later moved to clinical development leadership positions at Farmitalia Carlo Erba, Rhone-Poulenc and Aventis where he successfully developed oncology drugs at the global level.

During his career, he has authored or co-authored more than 100 oncology research manuscripts and abstracts. Dr. Riva is a member of the American Society of Clinical Oncology and the European Society for Medical Oncology.




What to read next



 LATEST MOVES FROM California 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy